Bioasis (BTI.V) is a company that is delivering hope to patients suffering with neurological diseases and disorders. It is the Blood-Brain Barrier delivery company. The Blood-Brain Barrier…
BIOAF
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain….
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an…
Bioasis Technologies (BTI.V) hired Shadow Lake Group, and affiliate, SLG Europe BV, as a business development adviser earlier this week, according to a press release. This one’s a…
Bioasis (TSXV:BTI; OTCQB:BIOAF), a biopharmaceutical company, has the potential to transform the treatment of brain disorders by bringing new, innovative technologies to the forefront. Their scientific research has led…
Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective…
Bioasis Technologies (BTI.V) announced they are entering into a research collaboration with Oxyrane UK. As Equity Guru previously reported, Bioasis is developing the xB³ platform, which aims penetrate the…
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according…
The New York Times went viral (shocker) in 2015 with their article covering psychologist Arthur Aron’s study on 36 questions that lead to love. #6 is the following: “If…